SYSTM Wealth Solutions LLC Buys 12,180 Shares of Natera, Inc. (NASDAQ:NTRA)

SYSTM Wealth Solutions LLC increased its stake in Natera, Inc. (NASDAQ:NTRA) by 3,592.9% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 12,519 shares of the medical research company’s stock after acquiring an additional 12,180 shares during the period. SYSTM Wealth Solutions LLC’s holdings in Natera were worth $1,356,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors also recently modified their holdings of NTRA. Norges Bank bought a new stake in shares of Natera in the 4th quarter valued at about $83,970,000. Perceptive Advisors LLC lifted its stake in shares of Natera by 289.7% in the 4th quarter. Perceptive Advisors LLC now owns 850,225 shares of the medical research company’s stock valued at $53,258,000 after acquiring an additional 632,047 shares during the last quarter. Vanguard Group Inc. lifted its stake in shares of Natera by 5.7% in the 4th quarter. Vanguard Group Inc. now owns 10,971,895 shares of the medical research company’s stock valued at $687,280,000 after acquiring an additional 588,147 shares during the last quarter. First Light Asset Management LLC lifted its stake in shares of Natera by 295.9% in the 1st quarter. First Light Asset Management LLC now owns 656,708 shares of the medical research company’s stock valued at $60,063,000 after acquiring an additional 490,822 shares during the last quarter. Finally, Farallon Capital Management LLC lifted its stake in shares of Natera by 13.0% in the 1st quarter. Farallon Capital Management LLC now owns 3,927,683 shares of the medical research company’s stock valued at $359,226,000 after acquiring an additional 452,800 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

Natera Stock Performance

Natera stock opened at $127.21 on Wednesday. The company has a quick ratio of 4.01, a current ratio of 4.14 and a debt-to-equity ratio of 0.34. The company has a market capitalization of $15.62 billion, a P/E ratio of -40.77 and a beta of 1.53. The stock’s 50 day moving average is $113.49 and its 200 day moving average is $104.74. Natera, Inc. has a twelve month low of $36.90 and a twelve month high of $132.01.

Natera (NASDAQ:NTRA) last posted its quarterly earnings results on Thursday, August 8th. The medical research company reported ($0.30) earnings per share for the quarter, topping the consensus estimate of ($0.69) by $0.39. The company had revenue of $413.35 million for the quarter, compared to the consensus estimate of $343.00 million. Natera had a negative return on equity of 36.74% and a negative net margin of 21.47%. The firm’s quarterly revenue was up 58.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted ($0.97) EPS. On average, equities research analysts predict that Natera, Inc. will post -1.96 earnings per share for the current fiscal year.

Insider Buying and Selling at Natera

In other Natera news, insider Jonathan Sheena sold 2,700 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $108.87, for a total transaction of $293,949.00. Following the sale, the insider now directly owns 301,808 shares in the company, valued at approximately $32,857,836.96. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. In other Natera news, CFO Michael Burkes Brophy sold 1,866 shares of the stock in a transaction on Wednesday, July 31st. The stock was sold at an average price of $99.65, for a total transaction of $185,946.90. Following the sale, the chief financial officer now directly owns 71,955 shares in the company, valued at approximately $7,170,315.75. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Jonathan Sheena sold 2,700 shares of the stock in a transaction on Monday, July 1st. The shares were sold at an average price of $108.87, for a total value of $293,949.00. Following the sale, the insider now owns 301,808 shares in the company, valued at $32,857,836.96. The disclosure for this sale can be found here. In the last three months, insiders have sold 86,197 shares of company stock worth $9,561,358. Insiders own 7.60% of the company’s stock.

Wall Street Analysts Forecast Growth

NTRA has been the subject of a number of recent analyst reports. Canaccord Genuity Group upped their price target on Natera from $130.00 to $145.00 and gave the company a “buy” rating in a research report on Tuesday, August 27th. Morgan Stanley upped their price target on Natera from $125.00 to $132.00 and gave the company an “overweight” rating in a research report on Tuesday, August 13th. Robert W. Baird upped their price target on Natera from $117.00 to $120.00 and gave the company an “outperform” rating in a research report on Friday, August 9th. Piper Sandler reaffirmed an “overweight” rating and set a $150.00 price target on shares of Natera in a research report on Friday, September 13th. Finally, StockNews.com lowered Natera from a “hold” rating to a “sell” rating in a research report on Wednesday, August 28th. One investment analyst has rated the stock with a sell rating and fifteen have assigned a buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus price target of $120.07.

Natera Profile

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.